Estrone (E1, Oestrone, Folliculin, CAS 53-16-7, C₁₈H₂₂O₂, MW 270.37 g/mol) is a naturally occurring C18 steroid estrogen and one of the three major endogenous estrogens in humans, alongside estradiol (E2) and estriol (E3). Chemically, estrone is 3-hydroxyestra-1,3,5(10)-trien-17-one. The defining structural feature that differentiates estrone from estradiol is the oxidation state at the C-17 position: estrone bears a ketone (C=O) at C-17, whereas estradiol bears a hydroxyl group (C-OH) at C-17. This single functional group difference has three pharmacologically decisive consequences: (1) Estrogen receptor binding affinity is reduced to approximately 4-12% of estradiol’s affinity for both ERα and ERβ, as the C-17 ketone cannot form the same hydrogen-bond network within the receptor’s ligand-binding domain that estradiol’s C-17 hydroxyl engages with His524. Despite this lower affinity, estrone achieves therapeutic ER activation through sustained target occupancy and the estrone-estradiol redox equilibrium maintained by 17-beta-HSD in target tissues. (2) The C-17 ketone makes estrone the ideal synthetic precursor for estradiol and its derivatives. Selective reduction of the C-17 ketone with sodium borohydride (NaBH₄) or enzymatic 17-beta-HSD yields 17-beta-estradiol in >90% yield with >98% diastereoselectivity for the 17-beta epimer. Ethynylation of the C-17 ketone with lithium acetylide yields ethinylestradiol, the estrogen component of all modern combined oral contraceptives. These high-yielding, stereoselective transformations make estrone the strategic starting material for industrial-scale estrogenic steroid manufacturing. (3) The oxidized C-17 position confers distinct metabolic handling. Estrone is interconvertible with estradiol in vivo via 17-beta-hydroxysteroid dehydrogenase (17-beta-HSD) enzymes, with the equilibrium favoring estrone in peripheral tissues and estradiol in the ovary and placenta. This estrone-estradiol redox pair constitutes the body’s endogenous estrogen buffer system. In premenopausal women, estradiol is the predominant circulating estrogen (30-400 pg/mL, produced by ovarian granulosa cells). After menopause, ovarian estradiol production declines by >90%, and estrone becomes the primary circulating estrogen at 30-70 pg/mL — 3-5× higher than postmenopausal estradiol concentrations (5-20 pg/mL). This physiological inversion, driven by peripheral aromatization of androstenedione in adipose tissue, makes estrone the natural, bioidentical estrogen for postmenopausal hormone replacement. UPOR Biotech supplies estrone pharmaceutical API at 97.0-103.0% HPLC purity (USP) under GMP with USP/BP/EP multi-compendial compliance.

Estrone exerts its therapeutic effects through binding and activation of estrogen receptors ERα and ERβ, which function as ligand-activated transcription factors in the nuclear receptor superfamily. The estrone-ER complex undergoes conformational change, dimerizes, translocates to the nucleus, and binds estrogen response elements (EREs) on DNA to regulate transcription of estrogen-responsive genes. Despite having 4-12% of estradiol’s binding affinity, estrone achieves therapeutic ER activation at clinical doses (0.625-1.25 mg/day oral) through sustained target occupancy, the high circulating concentrations achieved pharmacologically, and the estrone-estradiol redox equilibrium maintained by 17-beta-HSD in target tissues. The primary therapeutic applications are: (1) Hormone Replacement Therapy (HRT) for postmenopausal symptoms — estrone at 0.625-1.25 mg daily (oral) or 0.1% w/w (transdermal) significantly reduces vasomotor symptoms (hot flashes, night sweats) within 2-4 weeks by restoring hypothalamic thermoregulatory set-point via ERα activation in the preoptic nucleus. Vulvovaginal atrophy responds to topical estrone within 4-12 weeks through restoration of vaginal epithelial proliferation, glycogen content, and Lactobacillus-predominant flora. (2) Osteoporosis prevention — estrone activates ERα in osteoblasts, upregulating osteoprotegerin (OPG) which acts as a decoy receptor for RANKL, thereby inhibiting RANKL-RANK-mediated osteoclastogenesis and bone resorption. Continuous estrone therapy maintains or increases bone mineral density (BMD) by 2-5% at the lumbar spine and femoral neck over 2 years when initiated within 5 years of menopause. (3) Cardiovascular protection — ERα activation in vascular endothelial cells upregulates endothelial nitric oxide synthase (eNOS) via the PI3K/Akt pathway, promoting NO-mediated vasodilation. Estrone also modulates the lipid profile: increasing HDL-cholesterol by 10-15% and decreasing LDL-cholesterol by 10-15% through hepatic ERα-mediated regulation of apolipoprotein gene expression. The ‘timing hypothesis’ posits that cardiovascular benefit is realized when estrogen therapy is initiated within 5-10 years of menopause, before advanced atherosclerosis develops. (4) CNS and cognitive effects — ERβ is highly expressed in the hippocampus (CA1 and CA3 regions), prefrontal cortex, and basal forebrain cholinergic nuclei. Estrone’s CNS penetration supports cholinergic neuron survival, synaptic spine density maintenance, and cerebral glucose metabolism. (5) Urogenital atrophy (genitourinary syndrome of menopause, GSM) — topical estrone preparations restore vaginal epithelial thickness, maturation index, and lubrication through local ER activation without significant systemic exposure. Important safety consideration: As with all unopposed estrogen therapy, progestogen co-administration is required in women with an intact uterus to mitigate the 2- to 8-fold increased risk of endometrial hyperplasia and adenocarcinoma (per ACOG Practice Bulletin and NICE Guideline NG23). The estrone-to-estradiol conversion in target tissues via 17-beta-HSD type 1 provides a local reservoir of the more potent estradiol, amplifying the therapeutic signal at peripheral target sites while maintaining lower systemic estradiol exposure — a tissue-specific pharmacokinetic advantage not available with direct estradiol-only HRT formulations.

Estrone is the strategic starting material for the industrial synthesis of most clinically used estrogenic steroids because its C-17 ketone provides a versatile chemical handle for selective, high-yielding transformations. The synthetic pathways from estrone are: (1) 17-beta-Estradiol synthesis via selective C-17 ketone reduction — the C-17 ketone of estrone is stereoselectively reduced using sodium borohydride (NaBH₄, 1.0-1.5 equivalents) in methanol or ethanol at 0-5°C for 30-60 minutes, or via enzymatic reduction with 17-beta-hydroxysteroid dehydrogenase (17-beta-HSD) and NADH cofactor in aqueous buffer at pH 7.0-7.4. The reaction yields 17-beta-estradiol in >90% isolated yield with >98% diastereoselectivity for the 17-beta epimer. The ketone reduction is stereoelectronically controlled: hydride (or hydride-equivalent from NADH) delivery occurs preferentially from the less hindered alpha-face of the steroid nucleus (the face opposite the C-18 angular methyl group, which projects above the beta-face), producing the desired 17-beta-hydroxyl configuration. This selective reduction is the cornerstone transformation that makes estrone the preferred precursor over alternative synthetic routes (e.g., total synthesis from non-steroidal starting materials, which requires 15-20 synthetic steps vs 1 step from estrone). (2) Ethinylestradiol (EE) synthesis — estrone is ethynylated at C-17 using lithium acetylide-ethylenediamine complex (1.5-2.0 equivalents) in anhydrous THF or liquid ammonia at -40 to -20°C under inert atmosphere. The acetylide nucleophile attacks the C-17 ketone from the alpha-face, forming the 17-alpha-ethynyl-17-beta-hydroxy product (ethinylestradiol) with high stereoselectivity (>95% de). After aqueous workup and recrystallization (methanol/water), EE is obtained in 75-85% yield. The 17-alpha-ethynyl group is the critical structural feature that confers oral bioactivity by sterically blocking 17-beta-HSD-mediated oxidation at C-17, thereby preventing first-pass hepatic metabolism of the 17-beta-hydroxyl to the 17-keto (estrone) and substantially increasing oral bioavailability (from <5% for estradiol to 40-50% for EE). EE is the estrogen component of virtually all combined oral contraceptive (COC) formulations worldwide. (3) Estradiol ester synthesis — 17-beta-estradiol (obtained from estrone reduction) is esterified at the C-17 hydroxyl with the appropriate acid chloride or anhydride (e.g., valeryl chloride for estradiol valerate, cyclopentylpropionyl chloride for estradiol cypionate, benzoyl chloride for estradiol benzoate) in pyridine or dichloromethane with triethylamine base. These ester prodrugs, when formulated in oil solutions (e.g., sesame oil, castor oil/benzyl benzoate), provide sustained release from intramuscular depots with durations of action from 5-7 days (valerate) to 2-4 weeks (cypionate) to 3-4 weeks (enanthate), used in depot HRT and combined injectable contraceptives (e.g., estradiol cypionate/medroxyprogesterone acetate, Cyclofem/Lunelle). (4) Mestranol synthesis — the C-3 phenolic hydroxyl of ethinylestradiol is selectively methylated using dimethyl sulfate (1.1 equivalents) and potassium carbonate in acetone at reflux, yielding mestranol (the 3-methyl ether prodrug of EE) in 85-90% yield. Mestranol is a prodrug that undergoes hepatic O-demethylation (CYP3A4, CYP2C9) to EE in vivo. (5) Estrone sulfate and conjugated estrogens — sulfation of estrone at the C-3 hydroxyl using sulfur trioxide-pyridine complex or chlorosulfonic acid in pyridine yields estrone sulfate (as the sodium or piperazine salt), a component of conjugated equine estrogens (Premarin) and a water-soluble prodrug suitable for oral and injectable formulations. UPOR Biotech supplies pharmaceutical-grade estrone API with full characterization and DMF support, enabling pharmaceutical manufacturers to execute these downstream synthetic transformations with a high-purity, fully documented starting material.

The postmenopausal transition to estrone predominance is a fundamental endocrine shift driven by ovarian senescence and the emergence of peripheral aromatization as the primary estrogen biosynthetic pathway. In premenopausal women, estradiol (E2) is the dominant circulating estrogen, produced in the ovary through the two-cell, two-gonadotropin mechanism: theca interna cells (under LH stimulation, LH receptor/cAMP/PKA pathway) convert cholesterol to androstenedione via the steroidogenic cascade: cholesterol → pregnenolone (CYP11A1, mitochondrial) → 17-hydroxypregnenolone → dehydroepiandrosterone/DHEA (CYP17A1, 17,20-lyase activity) → androstenedione (3-beta-HSD). Androstenedione diffuses across the basement membrane to granulosa cells, where FSH (via FSH receptor/cAMP/PKA) upregulates aromatase (CYP19A1) expression. Aromatase converts androstenedione to estrone, and 17-beta-HSD type 1 (also FSH-upregulated in granulosa cells) reduces estrone to estradiol. Premenopausal estradiol concentrations range from 30-400 pg/mL (follicular phase) to 200-600 pg/mL (pre-ovulatory surge). After menopause (defined as 12 consecutive months of amenorrhea, typically age 45-55), primordial and primary ovarian follicles are depleted to near-zero. Granulosa cell numbers decline, aromatase expression in the ovary collapses, and the two-cell mechanism ceases. FSH levels rise dramatically to 30-150 mIU/mL (vs 2-10 mIU/mL premenopausal) due to loss of estradiol and inhibin B negative feedback on the hypothalamic GnRH pulse generator and anterior pituitary gonadotropes. Ovarian estradiol production decreases by >90%, and circulating estradiol falls to 5-20 pg/mL. However, androgen production does not cease. The ovarian theca-interstitial cells (under elevated postmenopausal LH) and the adrenal zona reticularis continue to produce androstenedione and testosterone at rates comparable to or slightly reduced from premenopausal levels. This androstenedione becomes the substrate for peripheral aromatization. The aromatase enzyme (CYP19A1) is expressed in multiple extra-ovarian tissues: adipose tissue (subcutaneous and visceral adipocytes and stromal vascular cells), skin fibroblasts, bone osteoblasts, vascular smooth muscle cells, and brain (hypothalamus, hippocampus, amygdala). In postmenopausal women, adipose tissue aromatase activity increases with age and with increasing BMI, making body fat mass the primary determinant of postmenopausal estrone levels. Obese postmenopausal women (BMI >30 kg/m²) have significantly higher estrone concentrations (80-120 pg/mL) compared to lean postmenopausal women (BMI <25 kg/m², 20-40 pg/mL). Peripheral aromatization of androstenedione to estrone accounts for >95% of circulating estrone production in postmenopausal women, with a conversion rate of approximately 1.5-2.5% of the androstenedione pool per 24 hours. The resulting estrone concentrations (30-70 pg/mL) exceed estradiol concentrations (5-20 pg/mL) by 3- to 5-fold, inverting the premenopausal estradiol:estrone ratio of approximately 2:1 to a postmenopausal ratio of approximately 1:3 to 1:5. Estrone produced in adipose tissue enters the circulation (primarily bound to albumin, ~60%, and sex hormone-binding globulin/SHBG, ~38%) and is delivered to target tissues (bone, brain, cardiovascular system, urogenital tract), where intracellular 17-beta-HSD type 1 reduces estrone to estradiol, and 17-beta-HSD type 2 oxidizes estradiol back to estrone. This peripheral-to-local conversion mechanism means that estrone functions as both a circulating hormone and a pro-hormone — a circulating reservoir that is activated to estradiol at the tissue level. The clinical significance is that estrone-based HRT provides the physiological estrogen that the postmenopausal body is already programmed to utilize, at the concentrations and tissue-distribution patterns established by endogenous postmenopausal physiology. UPOR Biotech’s pharmaceutical-grade estrone API supports the development of bioidentical, physiologically appropriate HRT formulations aligned with the endogenous postmenopausal estrogen profile, with the added advantage that tissue-level 17-beta-HSD conversion provides a built-in mechanism for local estradiol biosynthesis at target sites where higher ER activation is needed (e.g., bone, brain).

UPOR Biotech provides a complete GMP-compliant estrone API documentation package designed for seamless integration into regulatory submissions (ANDA Module 3.2.S, NDA, MAA) and customer quality systems: (1) Certificate of Analysis (COA) per batch — assay (97.0-103.0% HPLC, USP method), full impurity profile with RRT/RRF values, specific rotation (+158° to +165°, c=1, dioxane), melting point (258-260°C), loss on drying, water content, residual solvents (ICH Q3C Class 3), heavy metals (<10 ppm), elemental impurities (ICH Q3D), bacterial endotoxins (<5.0 EU/mg), and microbial panel (USP <61>/<62>). (2) Material Safety Data Sheet (MSDS/SDS) — GHS-compliant, 16-section format with handling recommendations for potent steroidal compounds (estrogenic compounds are readily absorbed through intact skin; appropriate PPE including nitrile gloves, lab coat, and safety glasses required; dedicated weighing area with local exhaust ventilation recommended). (3) Signed and dated HPLC chromatogram with integration parameters, system suitability data, and Estrone Reference Standard (USP/BP/EP) traceability. (4) GMP Compliance Certificate (ICH Q7). (5) ISO 9001:2015 Certificate. (6) USP/BP/EP Monograph Compliance Statement with individual monograph parameter conformance verification across all three compendia. (7) FDA Facility Registration Number. (8) BSE/TSE-Free Statement. (9) Nitrosamine Risk Assessment Report per FDA Guidance (February 2024) and EMA CHMP Guidance (Article 5(3) of Regulation (EC) No 726/2004). For estrone, the absence of secondary amine, tertiary amine, or nitrogen-containing functional groups in the molecular structure results in negligible nitrosamine formation risk; the documented risk assessment confirms this for regulatory completeness. (10) Elemental Impurities Compliance Statement (ICH Q3D) with risk assessment per USP <232>. (11) Residual Solvents Statement (ICH Q3C Class 3) — typical manufacturing solvents (ethanol, acetone) are Class 3 with low toxic potential and acceptable PDE limits per ICH Q3C. (12) Stability Data Package — real-time (36-month, 2-8°C, protected from light per ICH Q1A(R2)) and accelerated (6-month, 25°C/60%RH) with trend analysis per ICH Q1E. Estrone is a stable crystalline steroid; no significant degradation (<0.5% assay decrease) observed under recommended storage. Photostability per ICH Q1B confirms the requirement for light-protective packaging. (13) Complete Lot Traceability Documentation from starting material (androstenedione from phytosterol fermentation or total synthesis) through intermediate to finished API, including all in-process controls and critical process parameters. (14) Genotoxic Impurity Assessment per ICH M7. DMF support (Type II) is available with a Letter of Authorization for ANDA cross-reference. HALAL and KOSHER certificates provided upon request (applicable to fermentation-derived estrone). MOQ: 1 kg for commercial orders; 100 g for R&D characterization and method development samples. Free sample available for qualified B2B buyers — contact our sales team with your company profile, intended application, and target regulatory market. All documents are provided in English; certified translations available upon request for Spanish, Portuguese, Arabic, Japanese, and Korean regulatory submissions. Our facility undergoes regular customer and regulatory audits; audit reports and quality agreements are available upon execution of a Mutual Confidentiality Agreement (MCA). UPOR Biotech offers dedicated regulatory affairs support for ANDA filers, including DMF reference, CMC query responses, and post-approval change management. Every batch is shipped with complete documentation; electronic copies are provided within 24 hours of shipment confirmation.